- Home
- NVO
NVO
Novo Nordisk A/S
as 02-21-2025 4:00pm EST
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
| Founded: | 1923 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 530.0B | IPO Year: | N/A |
| Target Price: | $141.67 | AVG Volume (30 days): | 9.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 3.14 | EPS Growth: | 21.54 |
| 52 Week Low/High: | $77.82 - $148.15 | Next Earning Date: | 02-05-2025 |
| Revenue: | $40,314,376,667 | Revenue Growth: | 25.03% |
| Revenue Growth (this year): | 21.96% | Revenue Growth (next year): | 17.13% |
Latest Novo Nordisk A/S News
NVO Breaking Stock News: Dive into NVO Ticker-Specific Updates for Smart Investing
Reuters
19 hours ago
Shortage of Novo's Wegovy and Ozempic is resolved, FDA website shows
Insider Monkey
a day ago
Novo Nordisk A/S (NVO): Is It The Most Oversold Healthcare Stock to Buy Now?
GuruFocus.com
a day ago
Zealand Pharma AS (ZLDPF) Q4 2024 Earnings Call Highlights: Strong Cash Position and Obesity ...
Insider Monkey
2 days ago
Is Novo Nordisk A/S (NVO) the Best Global Stock to Buy According to Hedge Funds?
Zacks
2 days ago
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
MT Newswires
3 days ago
European Equities Close Lower in Wednesday Trading; UK Inflation Rises Higher Than Expected
MT Newswires
3 days ago
Update: Novo Nordisk Seeking $830 Million From Singapore Firm Over Alleged Fraud
MT Newswires
3 days ago
Novo Nordisk Seeking $830 Million From Singapore Firm Over Alleged Fraud
Compare NVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVO Novo Nordisk A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.